Incyte Announces FDA Approval of Zynyz® (retifanlimab-dlwr) Making it the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--FDA Approves Zynyz (retifanlimab-dlwr) the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States....

Business Wire - 5/15/2025 2:30:00 PM More News for INCY
Stock Analysis for INCY
Related Stocks: